Through precision molecular engineering, Aureka is developing a portfolio of first-in-class (FIC) and best-in-class (BIC) antibody therapeutics to address major unmet needs in obesity and cardiometabolic diseases, including pulmonary arterial hypertension and heart failure.

By uncovering novel immune regulatory design principles through combinatorial design and functional discovery, Aureka is developing differentiated antibody therapeutics that restore immune homeostasis and deliver broad, durable efficacy, with potential applications across a wide spectrum of inflammatory diseases, including AD, asthma, and COPD.

Aureka is developing next generation brain and tissue shuttles to deliver RNAs and biologics to treat a variety of CNS and aging-related diseases, with the goal of extending healthy lifespan and improving patient outcomes.